Precigen (PGEN) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precigen (PGEN) has outperformed Travere Therapeutics (TVTX) over the past year, gaining 136.0% versus a gain of 98.6%. Over five years, TVTX leads with a +112.4% price change compared with +63.4% for PGEN. Travere Therapeutics is the larger company by market cap ($4.91 billion vs $2.80 billion), about 1.8 times the size, while Precigen is growing revenue faster (+146.7% vs +110.5%).
Travere Therapeutics converts more of its revenue into profit, with a net margin of -5.2% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PGEN | TVTX |
|---|---|---|
| Share price | $7.81 | $52.13 |
| Market cap | $2.80B | $4.91B |
| 1-day change | +2.76% | +0.16% |
| YTD return | +81.82% | +36.19% |
| 1-year return | +136.02% | +98.63% |
| 5-year return | +63.44% | +112.41% |
| Forward P/E | — | 9.24 |
| EPS (TTM) | $-1.04 | $-0.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.68M | $490.73M |
| Revenue growth (YoY) | +146.73% | +110.45% |
| Net income (latest FY) | $-250.64M | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | -1141.13% | -12.80% |
| Net margin | -2588.21% | -5.21% |
| 52-week high | $8.98 | $68.73 |
| 52-week low | $2.99 | $22.59 |
| Distance from 52-week high | -13.03% | -24.16% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +74.78% | +44.29% |
| Average volume | 5.03M | 1.59M |
| Shares outstanding | 358.04M | 94.26M |
| Employees | 160 | 497 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed TVTX by 37.4 percentage points over the past year.
- Travere Therapeutics is more profitable, keeping -5.2 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- Precigen grew revenue faster in its latest fiscal year (+146.73% vs +110.45%).
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
PGEN vs TVTX FAQ
Which is bigger, Precigen or Travere Therapeutics?
Travere Therapeutics (TVTX) is larger, with a market capitalization of $4.91B compared with $2.80B for Precigen (PGEN).
Which stock has performed better over the past year, PGEN or TVTX?
PGEN returned +136.02% over the past 12 months, compared with +98.63% for TVTX (price return, excluding dividends). Past performance does not predict future results.
Are Precigen and Travere Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.